Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Gates Foundation digs down deep for TB

The fight against the global tuberculosis (TB) epidemic has received a huge boost in the form of a $280 million grant from the Bill & Melinda Gates Foundation.

20 Sep 2007

Spinal Muscular Atrophy Foundation and BG Medicine collaborate

The Spinal Muscular Atrophy Foundation and BG Medicine have announced a collaboration to discover plasma biomarkers of drug efficacy for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.

18 Sep 2007

GlaxoSmithKline to pursue novel antibacterial research program for DOD

GlaxoSmithKline has announced that it has signed an agreement with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD), to identify and develop a new class of antibacterials targeting both Gram negative biothreats and conventional Gram negative hospital pathogens.

18 Sep 2007

New Rensselaer tools speed stem cell research

Engineers at Rensselaer Polytechnic Institute have developed tools to help solve two of the main problems slowing the progress of stem cell research - how to quickly test stem cell response to different drugs or genes, and how to create a large supply of healthy, viable stem cells to study from only a few available cells.

13 Sep 2007

Innovative liquid crystal technology offers promise of new drugs

A partnership between Kent State University, Summa Health System and IC-MedTech Inc. has yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

10 Sep 2007

Hamburg to become Europe's hub of drug discovery

Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the northern German city's town hall today announcing the foundation of European ScreeningPort GmbH, a company that will run a state-of-the-art drug discovery service centre.

4 Sep 2007

Animal model for dengue research

A mosquito-borne disease often known as "break-bone fever" has found a new enemy in a unique type of mouse.

28 Aug 2007

Cancer Research Technology begins critical role in new Australian cancer research venture

Cancer Research Technology Ltd (CRT) today announces the start of its key role within an ambitious new Australia-based collaboration, Cancer Therapeutics CRC Pty Ltd (CTx), which commenced operations today.

28 Aug 2007

Cause of major subtype of glaucoma discovered

In a paper published in the journal Science, scientists from deCODE genetics and academic colleagues from the National University Hospital in Reykjavik and Uppsala University in Sweden report the discovery of two common single letter variations (SNPs) in the sequence of the human genome that appear to account for virtually all cases of a major subtype of glaucoma.

12 Aug 2007

Researchers watch bacteria and antibiotics at the atomic level

A new understanding of an enzyme important for the transfer of genetic information in bacteria may help scientists improve current antibiotics and also create antibiotics that are less vulnerable to resistance.

27 Jul 2007

Discovery of key HIV protein which makes cell membranes bend more easily

Carnegie Mellon University scientists have made an important discovery that aids the understanding of why HIV enters immune cells with ease.

26 Jul 2007

The future of Alzheimer's disease research

Imagine the day when a routine visit to the family doctor includes a simple blood test to predict the risk for developing Alzheimer's disease (AD).

26 Jul 2007

New algorithm matches any tumor cells to best possible anti-cancer treatments

Cancer patients don't have time to waste. Many go through several different treatments, however, to find one that is more effective against their particular type of tumor.

24 Jul 2007

Lubert Stryer wins National Medal of Science

Neurobiologist Lubert Stryer, MD, of the Stanford University School of Medicine, will receive the nation's highest scientific honor, the National Medal of Science, for his achievements in a wide range of fields that included the development of a DNA chip used in genetics.

19 Jul 2007

New approach for restless legs syndrome

Scientists at deCODE genetics ( NASDAQ:DCGN ) in collaboration with colleagues from Emory University today report the discovery of the first variant in the sequence of the human genome ever linked to risk of Restless Legs Syndrome (RLS) and Periodic Limb Movements (PLMs).

19 Jul 2007

Curry chemical bisdemethoxycurcumin may clear amyloid beta plaques

FINDINGS: Researchers isolated bisdemethoxycurcumin, the active ingredient of curcuminoids – a natural substance found in turmeric root – that may help boost the immune system in clearing amyloid beta, a peptide that forms the plaques found in Alzheimer's disease.

17 Jul 2007

Pieris progresses proprietary asthma program

Pieris AG, a bio-pharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma.

10 Jul 2007

Roche and Alnylam form RNAi therapeutics alliance

Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced today that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.

9 Jul 2007

Genetic mutation that may alter response to cancer therapeutics found

Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers.

4 Jul 2007

Ranbaxy receives tentative FDA approval for Tamsulosin capsules

Ranbaxy Pharmaceuticals has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg.

23 Jun 2007